Pharma and Biotech IP USA 2020

Memo

The life sciences are seeing developments in new technologies and undergoing a period of dramatic change and innovation, all of which are challenging traditional IP strategies and business models. IAM's inaugural Pharma and Biotech IP USA heads to Boston after four successful years in Europe bringing together leading in-house practitioners and expert counsel to explore next-generation strategies for protecting and exploiting cutting-edge innovation. Companies already confirmed to attend include: AbbVieAerie PharmaceuticalsAxcellaBayerBIOBoston ScientificBristol Myers SquibbEvelo BiosciencesGlaxoSmithKlineLonzaMerckNantWorksNovo NordiskPfizerPieris PharmaRecursion PharmaSynlogicThermo Fisher ScientificUSPTO Time: 08:00 to 18:50 Venue Name: TBC Prices:In-house counsel: USD 395.00,Law firms: USD 995.00,IP service providers: USD 1995.00